Catalyst Wire Dossier Catalyst Wire Dossier
FDA label_change · 2023-12-28

FDA Approved: NEBIVOLOL — Supplemental Application (Camber Pharmaceuticals, Inc.)

View source ↗

Summary

The FDA lists a Camber Pharmaceuticals supplemental application for Nebivolol, indicating a label update under the ANDA for Nebivolol.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Nebivolol (Nebivolol)

Snippet

SUPPL AP for NEBIVOLOL (NEBIVOLOL)